COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation
New financing will help COTA expand RWD platform & services to drive more efficient and inclusive drug development.
When it comes to cancer, there are a lot of myths and misconceptions out there. But the one thing is for certain: cancer can affect anyone, at any time, and from any background. Hear from one of our own about their battle with breast cancer and how early detection helped them defeat cancer.
Deloitte’s new Real-World Evidence Survey reveals that life sciences companies are now using real-world data (RWD) and real-world evidence (RWE) throughout the product life cycle—from early discovery through commercialization.
Innovation is the key to success in the life sciences industry. But with the vast amounts of data being generated by clinical trials and other research, it can be difficult to know where to focus your efforts. COTA’s tailored, fit-for-purpose real-world data (RWD) can help.
As artificial intelligence revolutionizes healthcare, we must develop a regulatory framework to ensure ethical use of patient data for research and care delivery. But, what should those guardrails look like, and how will we deploy them across the life sciences and clinical care industries? Miruna Sasu shares her thoughts on AI in healthcare and its efficacy with patient data.
COTA Research Showcased High Concordance Rate Between Real-World Physician Response Assessment & the 2017 European LeukemiaNet (ELN) Criteria for Acute Myeloid Leukemia at EHA2022
COTA researchers and collaborators’s recent abstract in the European Hematology Association’s library, found that overall agreement between response categories was 65.1% among AML data.
Friends of Cancer Research leads collaborative effort including COTA and nine other organizations to advance the collective understanding in applications of real-world data. New findings reveal further insights in non-small cell lung cancer (NSCLC) with a particular focus on novel treatment strategies.
Leading the data and digital team at Novartis, Bruno Villetelle believes that real world data should have a real world impact on patient care. He joins the #RealWorldTalk podcast to discuss how technology and data collection are being used at all stages of treatment to improve patients’ experiences and outcomes.
A recent observational study using real world data shows promising results from using tocilizumab in patients with severe COVID-19. According to study co-author Shivam Mathura, “While these results need to be further validated through clinical trials, we are thrilled to provide early insights to those in the field as we continue to fight this pandemic.”
COTA Featured in BioCentury – Real World Data’s Power to Increase Racial Diversity in Clinical Research
COTA’s Chief Medical Officer, Dr. C.K. Wang spoke with BioCentury to help further the conversation around the role of RWD in increasing racial diversity in clinical research.